All > Parkinsons Disease > Parkinson

Galvanic stimulation for Parkinson's Disease

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Parkinson's DiseaseGalvanic stimulation - Device
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will help determine if multimodal non-invasive neuromodulation can help improve symptoms in PD patients.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation
1
PD Patients treated with CereGate Software
1
High Fiber supplement

Study Objectives

4 Primary · 4 Secondary · Reporting Duration: Baseline to week 4

Baseline to week 4
Electroencephalography - amplitudes
Electroencephalography - latencies
MiniBESTest
Montreal Cognitive Assessment (MoCA)
NeuroCom Adaptation Test
NeuroCom Limits of Stability test (LOS)
NeuroCom Sensory Organization Test (SOT)
Unified Parkinson's Disease Rating Scale

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation
1
PD Patients treated with CereGate Software
1
High Fiber supplement

Trial Design

4 Treatment Groups

Physiotherapy only
1 of 4
Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)
1 of 4
Sham GVS (week 1) to active GVS (week 2)
1 of 4
Active GVS throughout weeks 1 + 2
1 of 4

Active Control

Experimental Treatment

32 Total Participants · 4 Treatment Groups

Primary Treatment: Galvanic stimulation · No Placebo Group · N/A

Active galvanic stimulation (GVS; week 1) to sham GVS (week 2)
Device
Experimental Group · 1 Intervention: Galvanic stimulation · Intervention Types: Device
Sham GVS (week 1) to active GVS (week 2)
Device
Experimental Group · 1 Intervention: Galvanic stimulation · Intervention Types: Device
Active GVS throughout weeks 1 + 2
Device
Experimental Group · 1 Intervention: Galvanic stimulation · Intervention Types: Device
Physiotherapy onlyNoIntervention Group · 1 Intervention: Physiotherapy only · Intervention Types:

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: baseline to week 4

Who is running the clinical trial?

Ryan D'ArcyLead Sponsor
Pacific Parkinson's Research InstituteUNKNOWN
University of British ColumbiaOTHER
1,325 Previous Clinical Trials
1,534,061 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be able to understand and complete all assessments (provided in English only).
You have idiopathic Parkinson's disease.
You must be able to voluntarily give informed consent.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top